 |
Doug Macron is the editor of GenomeWeb's Gene Silencing News. He covers research and therapeutic applications of RNAi, miRNA, and other gene-silencing technologies. E-mail Doug Macron or follow his GenomeWeb Twitter account at @Genesilencing. |
Traversa Responds to Former Execs Bid to Block Sale of IP in Bankruptcy Proceedings
August 23, 2012
Traversa Responds to Former Execs Bid to Block Sale of IP in Bankruptcy Proceedings
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Former Traversa Exec Moves to Block Sale of Certain IP in Bankruptcy Proceedings
August 16, 2012 / Gene Silencing News - Former Traversa Exec Forms New Company to Develop Oligo-modification Tech
May 16, 2013 / Gene Silencing News - Marina Defaults on Loan as Bankruptcy Looms
January 31, 2013 / Gene Silencing News - RNAi Drug Delivery Startup Solstice Closes $18M Series Financing Round
January 10, 2013 / Gene Silencing News - Marina Says Cash Will Run out at the End of the Month, Reports 2011 Financials
October 18, 2012 / Gene Silencing News